Accelerated Approval Remains “Viable Pathway,” FDA’s Woodcock Says

FDA’s accelerated approval program is alive and well now, and will remain a viable pathway in the future, despite concerns within the industry and investor communities that recent oncology regulatory actions are hastening the program’s demise.